Form 4: Edwards Lifesciences Executive Stock Transaction

Donald E. Bobo Jr., CVP of Strategy and Corporate Development at Edwards Lifesciences, reported a routine disposition of shares to cover tax obligations.

Summary

• Donald E. Bobo Jr. disposed of 469 shares of Edwards Lifesciences (EW) common stock on May 3, 2026.
• The transaction was executed at a price of $83.98 per share.
• The disposition was categorized under transaction code 'F', indicating the payment of tax liability by delivering or withholding securities incident to the vesting of a security.
• Following this transaction, the reporting person maintains direct ownership of 20,797.2532 shares.
• The reporting person also holds indirect interests, including 38,969.5756 shares in a 401(k) plan and 121,756 shares held in a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative transaction rather than a strategic or market-driven move.

Positives

• The transaction is a routine administrative action related to tax withholding rather than a discretionary sale of shares.
• The reporting person retains a significant equity stake in the company across direct and indirect holdings.

Negatives

• None identified; this is a standard regulatory filing for tax-related share withholding.

Risks

• None identified; this filing pertains to individual ownership changes and does not reflect operational or market risks.

Future Outlook

Not applicable; this is a retrospective disclosure of a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that routine Form 4 filings involving tax withholding upon the vesting of equity awards are standard practice for corporate executives and do not typically signal changes in management sentiment or company outlook.

Comparison to Industry Standards

• The filing follows standard SEC disclosure requirements for executive compensation and equity management.
• The use of transaction code 'F' is consistent with industry-standard practices for managing tax obligations related to restricted stock unit (RSU) vesting.

Stakeholder Impact

• No material impact on shareholders, employees, or other stakeholders as this is a routine personal financial transaction.

Key Dates

Keywords

Edwards Lifesciences, EW, Form 4, Insider Trading, Stock Ownership, Corporate Governance